Lipella Pharma Shares Rise After Positive Trial Data for Oral Lichen Planus Treatment
Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse ...
All Penny Stocks (English) on MSN3d
Biotech Rips On Topline Analysis
A biotech company is turning heads so far during Tuesday’s session after it shared topline analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 ...
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key MetricsFindings Highlight ...
Lipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trial
Lipella Pharmaceuticals (LIPO) shared topline analysis of its Phase 2a multicenter dose-ranging trial examining LP-310, a liposomal-tacrolimus ...